You are here
EU rejects criticism for slow vaccine rollout across bloc
Mon, 2021-01-04 10:10 — mike kraftBRUSSELS (AP) — The European Commission defended its coronavirus vaccination strategy Monday amid growing criticism in member states about the slow rollout of COVID-19 shots across the region of 450 million inhabitants.
Vaccinations programs in the 27 nation-bloc have gotten off to a slow start and some EU members have been quick to blame the EU’s executive arm for a perceived failure of delivering the right amount of doses. In Finland, health authorities are reportedly unhappy that the country only received about 40,000 doses in December, instead of the 300,000 that were expected.
Facing a barrage of questions on vaccines during a news conference, EU Commission spokesman Eric Mamer said the main problem with the deployment of vaccination programs “is an issue of production capacity, an issue that everybody is facing.”
“We have actually signed contracts that would allow member states to get access to 2 billion doses, largely enough to vaccinate the whole of the EU population,” he said.
As part of its strategy, the EU has sealed six vaccines contracts, with Moderna, AstraZeneca, Sanofi-GSK, Janssen Pharmaceutica NV, Pfizer-BioNTech and CureVac. But only the Pfizer-BioNTech vaccine has been approved for use so far in the 27-nation bloc.
The European Medicines Agency said its human medicines committee, CHMP, was meeting Monday “to discuss the Moderna vaccine.” The Amsterdam-based agency had been scheduled to discuss authorizing the U.S. company’s vaccine for use in the EU on Wednesday. ...
ALSO SEE: UK first in world to start using Oxford-AstraZeneca vaccine
Recent Comments